Showing results (1001-1010 of 1,894) with videos related to
Sort By:
Pageof 190
Alzheimer Disease and Associated Disorders|February 24, 2006
Neuropathologic correlates of activities of daily living in Alzheimer diseaseGad A Marshall, Lynn A Fairbanks, Sibel Tekin, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer diseaseB P Imbimbo, U Lucca, F Lucchelli, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
Presentation and stability of noncognitive symptom patterns in patients with Alzheimer diseaseM Haupt, M Jänner, S Ebeling, et al.Alzheimer Disease and Associated Disorders|January 7, 1999
Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer diseaseN Hirono, E Mori, M Yasuda, et al.Alzheimer Disease and Associated Disorders|January 1, 1995
Clinicopathologic study of probable Alzheimer disease: assessment of criteria for excluding cerebrovascular diseaseS Sevush, R Durara, J Rivero, et al.Alzheimer Disease and Associated Disorders|January 1, 1996
Hereditary cerebral hemorrhage with amyloidosis-Dutch type: better correlation of cognitive deterioration with advancing age than with number of focal lesions or white matter hyperintensitiesM Bornebroek, M A Van Buchem, J Haan, et al.Alzheimer Disease and Associated Disorders|January 1, 1996
Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer diseaseR G Gonzalez, A R Guimaraes, G J Moore, et al.Alzheimer Disease and Associated Disorders|January 1, 1996
Potential prevention of Alzheimer disease and dementiaL H KullerAlzheimer Disease and Associated Disorders|January 1, 1996
Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer diseaseS Gauthier, J Montplaisir, D Petit, et al.Alzheimer Disease and Associated Disorders|January 1, 1996
Issues in accelerating the pace of development for neuroprotective agentsK L DavisPageof 190